Bavarian Nordic AS - Company Profile
Powered by 
All the sales intelligence you need on Bavarian Nordic AS in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Bavarian Nordic AS fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Bavarian Nordic AS.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Bavarian Nordic AS (Bavarian Nordic) is a biotechnology company engaged in the research, development, and manufacturing of vaccines. The company's primary activities include producing vaccines for infectious diseases, with a focus on live-virus vaccines. Its major products include vaccines for smallpox, monkeypox, rabies, cholera, typhoid, and tick-borne encephalitis. The company offers its products under various brands, including Jynneos, Imvamune, Imvanex, Rabipur, Rabavert, Vaxchora, and Vivotif. The company's vaccines are primarily offered to governments and international organizations for public health preparedness and are also available for travelers and at-risk populations. The company operates its commercial-scale manufacturing facility in Kvistgaard, Denmark. It has operational presence in Canada, Switzerland, Germany, Italy, Spain, and Sweden. Bavarian Nordic is headquartered in Hellerup, Denmark.
Headquarters
Denmark
Address
Philip Heymans Alle 3, Hellerup, DK-2900
Website
www.bavarian-nordic.com
Telephone
45 33268383
No of Employees
1,861
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BAVA (CPH)
Revenue (2024)
$943.9M
9.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
39.2%
(2024 vs 2023)
Market Cap*
$2.1B
Net Profit Margin (2024)
XYZ
27.5%
(2024 vs 2023)
* As of and is in US$
Bavarian Nordic AS premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Encepur: Tick-borne Encephalitis Vaccine | Encepur |
| JYNNEOS / IMVAMUNE / IMVANEX: Smallpox +/- Monkeypox Vaccine | JYNNEOS |
| Rabipur / RabAvert: Rabies Vaccine | IMVAMUNE |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In June, the company received approval from Health Canada for VIMKUNYA (recombinant, adsorbed) for immunization to prevent disease caused by chikungunya virus infection for individuals 12 years of age and older. |
| 2026 | Contracts/Agreements | In June, the company secured a government contract to deliver its MVA-BN smallpox/mpox vaccine. |
| 2026 | Regulatory Approval | In April, the company received approval from the Swiss Agency for Therapeutic Products, Swissmedic, for VIMKUNYA (recombinant, adsorbed) for active immunization to prevent disease caused by the chikungunya virus. |
Competitor Comparison
| Key Parameters | Bavarian Nordic AS | BioNTech SE | Moderna Inc | Novavax Inc | Icosavax Inc |
|---|---|---|---|---|---|
| Headquarters | Denmark | Germany | United States of America | United States of America | United States of America |
| City | Hellerup | Mainz | Cambridge | Gaithersburg | Seattle |
| State/Province | - | Rheinland-Pfalz | Massachusetts | Maryland | Washington |
| No. of Employees | 1,861 | 7,807 | 4,700 | 749 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Anne Louise Eberhard | Chairman | Executive Board | 2025 | 63 |
| Heidi Hunter | Vice Chairman | Executive Board | 2025 | 68 |
| Paul Chaplin | Chief Executive Officer; President | Senior Management | 2014 | 59 |
| Henrik Juuel | Chief Financial Officer; Executive Vice President | Senior Management | 2018 | 61 |
| Russell Thirsk | Chief Operating Officer; Executive Vice President | Senior Management | 2022 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer